- Home
- FBP vs ARQT Comparison
FBP vs ARQT Comparison
Compare FBP & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBP | ARQT |
|---|---|---|
| Founded | 1948 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.3B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FBP | ARQT |
|---|---|---|
| Price | $20.57 | $24.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $24.13 | ★ $31.86 |
| AVG Volume (30 Days) | 986.4K | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-25-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | 18.78 | ★ 88.79 |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $1,255,034,000.00 | $376,072,000.00 |
| Revenue This Year | $15.10 | $34.46 |
| Revenue Next Year | $4.56 | $29.77 |
| P/E Ratio | $9.58 | ★ N/A |
| Revenue Growth | 2.38 | ★ 91.34 |
| 52 Week Low | $16.40 | $11.86 |
| 52 Week High | $23.43 | $31.77 |
Technical Indicators
Market Signals| Indicator | FBP | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 43.32 |
| Support Level | $19.46 | $22.26 |
| Resistance Level | $20.64 | $27.65 |
| Average True Range (ATR) | 0.62 | 1.54 |
| MACD | -0.22 | -0.18 |
| Stochastic Oscillator | 25.25 | 28.91 |
Price Performance
Historical ComparisonAbout FBP First BanCorp. New
First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.